• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

伊朗非酒精性脂肪性肝病和非酒精性脂肪性肝炎患者肠道微生物组组成的特征。

Characterization of gut microbiome composition in Iranian patients with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

机构信息

Foodborne and Waterborne Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Micalis Institute, INRAE, AgroParisTech, Paris-Saclay University, Jouy-en-Josas, France.

出版信息

Sci Rep. 2023 Nov 23;13(1):20584. doi: 10.1038/s41598-023-47905-z.

DOI:10.1038/s41598-023-47905-z
PMID:37996480
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10667333/
Abstract

Gut microbiota dysbiosis is intimately associated with development of non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Nevertheless, the gut microbial community during the course of NAFLD and NASH is yet to be comprehensively profiled. This study evaluated alterations in fecal microbiota composition in Iranian patients with NAFLD and NASH compared with healthy individuals. This cross-sectional study enrolled 15 NAFLD, 15 NASH patients, and 20 healthy controls, and their clinical parameters were examined. The taxonomic composition of the fecal microbiota was determined by sequencing the V3-V4 region of 16S rRNA genes of stool samples. Compared to the healthy controls, NAFLD and NASH patients presented reduced bacterial diversity and richness. We noticed a reduction in the relative abundance of Bacteroidota and a promotion in the relative abundance of Proteobacteria in NAFLD and NASH patients. L-histidine degradation I pathway, pyridoxal 5'-phosphate biosynthesis I pathway, and superpathway of pyridoxal 5'-phosphate biosynthesis and salvage were more abundant in NAFLD patients than in healthy individuals. This study examined fecal microbiota dysbiosis in NAFLD and NASH patients and presented consistent results to European countries. These condition- and ethnicity-specific data could provide different diagnostic signatures and therapeutic targets.

摘要

肠道微生物失调与非酒精性脂肪性肝病(NAFLD)和非酒精性脂肪性肝炎(NASH)的发展密切相关。然而,NAFLD 和 NASH 过程中的肠道微生物群落尚未得到全面描述。本研究评估了与健康个体相比,伊朗 NAFLD 和 NASH 患者粪便微生物群落组成的变化。这项横断面研究纳入了 15 名 NAFLD 患者、15 名 NASH 患者和 20 名健康对照者,并检查了他们的临床参数。通过对粪便样本 16S rRNA 基因的 V3-V4 区进行测序,确定粪便微生物的分类组成。与健康对照组相比,NAFLD 和 NASH 患者的细菌多样性和丰富度降低。我们注意到,在 NAFLD 和 NASH 患者中,拟杆菌门的相对丰度降低,变形菌门的相对丰度增加。L-组氨酸降解 I 途径、吡哆醛 5'-磷酸生物合成 I 途径和吡哆醛 5'-磷酸生物合成和回收的超级途径在 NAFLD 患者中比在健康个体中更为丰富。本研究检查了 NAFLD 和 NASH 患者的粪便微生物失调,并呈现出与欧洲国家一致的结果。这些与疾病和种族相关的数据可能提供不同的诊断特征和治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98c6/10667333/33d6edb802e1/41598_2023_47905_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98c6/10667333/e6b1897d7e07/41598_2023_47905_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98c6/10667333/219261c8b426/41598_2023_47905_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98c6/10667333/576c82fe2ad0/41598_2023_47905_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98c6/10667333/1c3fb5e4e206/41598_2023_47905_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98c6/10667333/b446b03e5162/41598_2023_47905_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98c6/10667333/aebe27399aa3/41598_2023_47905_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98c6/10667333/33d6edb802e1/41598_2023_47905_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98c6/10667333/e6b1897d7e07/41598_2023_47905_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98c6/10667333/219261c8b426/41598_2023_47905_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98c6/10667333/576c82fe2ad0/41598_2023_47905_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98c6/10667333/1c3fb5e4e206/41598_2023_47905_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98c6/10667333/b446b03e5162/41598_2023_47905_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98c6/10667333/aebe27399aa3/41598_2023_47905_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98c6/10667333/33d6edb802e1/41598_2023_47905_Fig7_HTML.jpg

相似文献

1
Characterization of gut microbiome composition in Iranian patients with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.伊朗非酒精性脂肪性肝病和非酒精性脂肪性肝炎患者肠道微生物组组成的特征。
Sci Rep. 2023 Nov 23;13(1):20584. doi: 10.1038/s41598-023-47905-z.
2
Gut Microbiota Dysbiosis in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study in Taiwan.台湾经活检证实的非酒精性脂肪性肝病患者的肠道微生物失调:一项横断面研究。
Nutrients. 2020 Mar 19;12(3):820. doi: 10.3390/nu12030820.
3
Microbiome Signatures Associated With Steatohepatitis and Moderate to Severe Fibrosis in Children With Nonalcoholic Fatty Liver Disease.与儿童非酒精性脂肪性肝病患者的脂肪性肝炎和中重度纤维化相关的微生物组特征。
Gastroenterology. 2019 Oct;157(4):1109-1122. doi: 10.1053/j.gastro.2019.06.028. Epub 2019 Jun 27.
4
The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota.非酒精性脂肪性肝病的严重程度与肠道菌群失调及肠道微生物群代谢功能的改变有关。
Hepatology. 2016 Mar;63(3):764-75. doi: 10.1002/hep.28356. Epub 2016 Jan 13.
5
Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.了解肠道微生物组和微生物代谢物在非酒精性脂肪性肝病中的作用:当前的证据和观点。
Biomolecules. 2021 Dec 31;12(1):56. doi: 10.3390/biom12010056.
6
Role of intestinal flora in the development of nonalcoholic fatty liver disease in children.肠道菌群在儿童非酒精性脂肪性肝病发病机制中的作用。
Microbiol Spectr. 2024 Feb 6;12(2):e0100623. doi: 10.1128/spectrum.01006-23. Epub 2024 Jan 8.
7
Longitudinal 16S rRNA Sequencing Reveals Relationships among Alterations of Gut Microbiota and Nonalcoholic Fatty Liver Disease Progression in Mice.纵向 16S rRNA 测序揭示了肠道微生物群的变化与小鼠非酒精性脂肪性肝病进展之间的关系。
Microbiol Spectr. 2022 Jun 29;10(3):e0004722. doi: 10.1128/spectrum.00047-22. Epub 2022 Jun 1.
8
Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice.回肠胆汁酸转运蛋白抑制剂通过改善非酒精性脂肪性肝病模型小鼠肠道微生物失调改善肝脂肪变性。
mBio. 2021 Aug 31;12(4):e0115521. doi: 10.1128/mBio.01155-21. Epub 2021 Jul 6.
9
Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease.非酒精性脂肪性肝病患者的肠道菌群失调。
Hepatobiliary Pancreat Dis Int. 2017 Aug 15;16(4):375-381. doi: 10.1016/S1499-3872(17)60019-5.
10
Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach.采用综合宏基因组学方法分析小儿非酒精性脂肪肝和肥胖患者的肠道微生物组。
Hepatology. 2017 Feb;65(2):451-464. doi: 10.1002/hep.28572. Epub 2016 Jun 2.

引用本文的文献

1
Modulation of Gut Microbial Composition by subsp. CKDB001 Supplementation in a High-Fat-Diet-Induced Obese Mice.在高脂饮食诱导的肥胖小鼠中,补充副干酪乳杆菌亚种CKDB001对肠道微生物组成的调节作用
Nutrients. 2025 Jul 7;17(13):2251. doi: 10.3390/nu17132251.
2
Gut microbiota and blood metabolites: unveiling their roles in hippocampal volume changes through Mendelian randomization and mediation analysis.肠道微生物群与血液代谢物:通过孟德尔随机化和中介分析揭示它们在海马体体积变化中的作用。
Metab Brain Dis. 2025 Apr 12;40(4):178. doi: 10.1007/s11011-025-01611-z.
3
Lactiplantibacillus plantarum FRT4 protects against fatty liver hemorrhage syndrome: regulating gut microbiota and FoxO/TLR-4/NF-κB signaling pathway in laying hens.

本文引用的文献

1
Intestinal microbiota changes pre- and post-fecal microbiota transplantation for treatment of recurrent infection among Iranian patients with concurrent inflammatory bowel disease.伊朗炎症性肠病并发复发性感染患者粪便微生物群移植前后的肠道微生物群变化
Front Microbiol. 2023 Feb 24;14:1147945. doi: 10.3389/fmicb.2023.1147945. eCollection 2023.
2
Machine learning classifiers for screening nonalcoholic fatty liver disease in general adults.机器学习分类器在一般成年人中非酒精性脂肪性肝病筛查中的应用。
Sci Rep. 2023 Mar 3;13(1):3638. doi: 10.1038/s41598-023-30750-5.
3
A metagenomic study identifies a Prevotella copri enriched microbial profile associated with non-alcoholic steatohepatitis in subjects with obesity.
植物乳杆菌FRT4可预防脂肪肝出血综合征:调节蛋鸡肠道微生物群及FoxO/TLR-4/NF-κB信号通路
Microbiome. 2025 Mar 29;13(1):88. doi: 10.1186/s40168-025-02083-0.
4
Randomised double-blind placebo-controlled trial protocol to evaluate the therapeutic efficacy of lyophilised faecal microbiota capsules amended with next-generation beneficial bacteria in individuals with metabolic dysfunction-associated steatohepatitis.评估冻干粪便微生物群胶囊添加新一代有益细菌对代谢功能障碍相关脂肪性肝炎患者治疗效果的随机双盲安慰剂对照试验方案
BMJ Open. 2025 Jan 9;15(1):e088290. doi: 10.1136/bmjopen-2024-088290.
5
Impact of TNF and IL-33 Cytokines on Mast Cells in Neuroinflammation.TNF 和 IL-33 细胞因子对神经炎症中肥大细胞的影响。
Int J Mol Sci. 2024 Mar 13;25(6):3248. doi: 10.3390/ijms25063248.
一项宏基因组学研究鉴定出与肥胖人群非酒精性脂肪性肝炎相关的富含普雷沃氏菌属的微生物特征。
J Gastroenterol Hepatol. 2023 May;38(5):791-799. doi: 10.1111/jgh.16147. Epub 2023 Mar 2.
4
Identification of Gut Microbial Lysine and Histidine Degradation and CYP-Dependent Metabolites as Biomarkers of Fatty Liver Disease.鉴定肠道微生物赖氨酸和组氨酸降解物及 CYP 依赖性代谢产物作为非酒精性脂肪性肝病的生物标志物。
mBio. 2023 Feb 28;14(1):e0266322. doi: 10.1128/mbio.02663-22. Epub 2023 Jan 30.
5
Machine learning-derived gut microbiome signature predicts fatty liver disease in the presence of insulin resistance.机器学习衍生的肠道微生物组特征可预测存在胰岛素抵抗的脂肪肝疾病。
Sci Rep. 2022 Dec 17;12(1):21842. doi: 10.1038/s41598-022-26102-4.
6
Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications.非酒精性脂肪性肝病中的肠道菌群失调:发病机制、诊断和治疗意义。
Front Cell Infect Microbiol. 2022 Nov 8;12:997018. doi: 10.3389/fcimb.2022.997018. eCollection 2022.
7
Genetic variants in promoter region of is associated with the risk of non-alcoholic fatty liver disease in a Chinese Han population: a case-control study.在中国汉族人群中,[基因名称]启动子区域的遗传变异与非酒精性脂肪性肝病风险相关:一项病例对照研究。 (你原文中“of”后面缺少具体基因名称,请补充完整以便翻译更准确)
Gastroenterol Rep (Oxf). 2022 Oct 31;10:goac060. doi: 10.1093/gastro/goac060. eCollection 2022.
8
Co-administration of ursodeoxycholic acid with rosuvastatin/ezetimibe in a non-alcoholic fatty liver disease model.在非酒精性脂肪性肝病模型中熊去氧胆酸与瑞舒伐他汀/依折麦布的联合应用。
Gastroenterol Rep (Oxf). 2022 Aug 13;10:goac037. doi: 10.1093/gastro/goac037. eCollection 2022.
9
Approaches to discern if microbiome associations reflect causation in metabolic and immune disorders.探讨微生物组关联是否反映代谢和免疫紊乱因果关系的方法。
Gut Microbes. 2022 Jan-Dec;14(1):2107386. doi: 10.1080/19490976.2022.2107386.
10
Effect of Fecal Microbiota Transplantation on Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial.粪便微生物移植治疗非酒精性脂肪性肝病的随机临床试验。
Front Cell Infect Microbiol. 2022 Jul 4;12:759306. doi: 10.3389/fcimb.2022.759306. eCollection 2022.